Nonsteroidal anti-inflammatory drugs in schizophrenia: Ready for practice or a good start? A meta-analysis

Journal of Clinical Psychiatry

Volumn 73, Issue 4, 2012, Pages 414-419

  Sommer, Iris E ^a   De Witte, Lot ^a   Begemann, Marieke ^a   Kahn, René S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMISULPRIDE; CELECOXIB; CLOZAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84860544826     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.10r06823     Document Type: Article

References (47)

1. Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different cultures: a World Health Organization ten-country study. Psychol Med Monogr suppl. 1992;20:1-97. doi:10.1017/S026418010904 PubMed
2. Ayuso-Mateos J. Global burden of schizophrenia in the year 2000. Available at: http://www.who.int/evidence/bod. Accessed October 1, 2011.
3. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts" 5. Treatment and prevention: past, present, and future. Schizophr Res. 2010;122(1-3):1-23. doi:10.1016/j.schres.2010.05.025 PubMed
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131. doi:10.101/archpsyc.64.10.123 PubMed (Pubitemid 47529346)
5. Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010;23(2):103-111. doi:10.1097/YCO.0b013e32836427 PubMed
6. Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: a randomized double-blind placebo-controlled trial. Psychiatry Res. 2010; 179(1):19-23. doi:10.1016/j.psychres.2010.04.035 PubMed
7. Schwarz C, Volz A, Li C, et al. Valproate for schizophrenia. Cochrane Database Syst Rev. 2008;(3):CD004028. PubMed
8. Citrome L. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? J Clin Psychiatry. 2009;70(6):932-933. doi:10.408/JCP.09ac05289 PubMed
9. Volz A, Khorsand V, Gillies D, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2007;(1):CD006391. PubMed
10. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res. 1998;30(3):193-208. doi:10.1016/S0920-964(97)0151-5 PubMed (Pubitemid 28189552)
11. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry. 1999;56(9):836-841. doi:10.101/archpsyc.56.9.836 PubMed
12. Müller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev. 2010;6(3):213-220. PubMed doi:10.2174/15739510791823673
13. Eaton WW, Byrne M, Ewald H, et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry. 2006;163(3):521-528. doi:10.176/api.ajp.163.3.521 PubMed (Pubitemid 44469397)
14. Knight JG, Menkes DB, Highton J, et al. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry. 2007;12(5):424-431. PubMed (Pubitemid 46652460)
15. Laan W, Selten JP, Grobbee DE, et al. Non-steroidal anti-inflammatory drugs and the risk of psychosis. Eur Neuropsychopharmacol. 2007;17(4):309-311. doi:10.1016/j.euroneuro.206.09.03 PubMed (Pubitemid 46156993)
16. Laan W, Smeets H, de Wit NJ, et al. Glucocorticosteroids associated with a decreased risk of psychosis. J Clin Psychopharmacol. 2009;29(3):288-290. doi:10.1097/JCP.0b013e3181a4575 PubMed
17. Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167(3):261-280. doi:10.176/api.ajp.209.09030361 PubMed
18. Torrey EF, Bartko JJ, Lun ZR, et al. Antibodies to toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(3):729-736. doi:10.1093/schbul/sbl050 PubMed (Pubitemid 47343710)
19. van Berckel BN, Bossong MG, Boellaard R, et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry. 2008;64(9):820-822. doi:10.1016/j.biopsych. 208.04.025 PubMed
20. Doorduin J, de Vries EF, Willemsen AT, et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009;50(11):1801-1807. doi:10.2967/jnumed.109.0647 PubMed
21. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63(3):257-265. doi:10.1/j.140-1819.209.01945.x PubMed
22. Stefansson H, Ophoff RA, Steinberg S, et al Genetic Risk and Outcome in Psychosis (GROUP). Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744-747. PubMed
23. Bechter K, Reiber H, Herzog S, et al. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res. 2010;44(5):321-330. doi:10.1016/j.jpsychires.209.08.08 PubMed
24. Riedel M, Strassnig M, Schwarz MJ, et al. COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date. CNS Drugs. 2005;19(10):805-819. doi:10.2165/023210-2051910-01 PubMed (Pubitemid 43138335)
25. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med. 1991;324(24):1716-1725. PubMed
26. Moher D, Liberati A, Tetzlaff J, et al PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi:10.136/bmj.b2535 PubMed
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
28. Lipsey MW, Wilson DB. Practical Meta-Analysis. Thousand Oaks, CA: Sage; 2001.
29. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276. PubMed (Pubitemid 18039085)
30. Andreasen NC. Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa; 1984.
31. Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.
32. Shadish WR. HACK. Combining estimates of effect size. In: Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation; 1994:261-281.
33. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560. doi:10.136/bmj.327.7414.57 PubMed (Pubitemid 37088507)
34. Borenstein M, Hedges L, Higgins J, et al. Comprehensive Meta-Analysis Version 2. Engelwood, NJ: Biostat Inc; 2010.
35. Müller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029-1034. doi:10.176/api.ajp.159.6. 1029 PubMed (Pubitemid 34586950)
36. Rapaport MH, Delrahim KK, Bresee CJ, et al. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry. 2005;57(12):1594-1596. doi:10.1016/j.biopsych.205.02.024 PubMed (Pubitemid 40805391)
37. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90(1-3):179-185. doi:10.1016/j.schres.206.1.016 PubMed (Pubitemid 46177578)
38. Müller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121(1-3):118-124. doi:10.1016/j.schres.2010.04.015 PubMed
39. Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71(5):520-527. doi:10.408/JCP.09m0517yel PubMed
40. Emerson GB, Warme WJ, Wolf FM, et al. Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial. Arch Intern Med. 2010;170(21):1934-1939. doi:10.101/archinternmed.2010.406 PubMed
41. Munafò MR, Flint J. How reliable are scientific studies? Br J Psychiatry. 2010;197(4):257-258. doi:10.192/bjp.bp.109.069849 PubMed
42. Yokota O, Terada S, Ishihara T, et al. Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):715-721. doi:10.1016/j.pnpbp.204.05.018 PubMed (Pubitemid 38987397)
43. Bresee CJ, Delrahim K, Maddux RE, et al. The effects of celecoxib augmentation on cytokine levels in schizophrenia. Int J Neuropsychopharmacol. 2006;9(3):343-348. doi:10.1017/S14614570505808 PubMed (Pubitemid 43780502)
44. Tran E, Rouillon F, Loze JY, et al. Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer. 2009;115(15):3555- 3562. doi:10.102/cncr.24383 PubMed
45. Jin H, Folsom D, Sasaki A, et al. Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res. 2011;125(2-3):295-299. doi:10.1016/j.schres.2010.10.029 PubMed
46. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741-1750. doi:10.1016/S0140-6736(10)61543-7 PubMed
47. Chakraborti AK, Garg SK, Kumar R, et al. Progress in COX-2 inhibitors: a journey so far. Curr Med Chem. 2010;17(15):1563-1593. doi:10.2174/ 09298671079097980 PubMed